Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: A meta-analysis of controlled clinical trials

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 1-10

  Alavian, Seyed Moayed ^a   Tabatabaei, Seyed Vahid ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HBV vaccine; levamisole; meta analysis; vaccine adjuvant

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; LEVAMISOLE;

ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; HEPATITIS B; HUMAN; IMMUNOLOGY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE, CHRONIC; LEVAMISOLE; PROSPECTIVE STUDIES; RENAL DIALYSIS;

MLCS; MLOWN;

EID: 77952301857     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.005     Document Type: Review

References (57)

1. Espinosa, M, Martn-Malo, A, Ojeda, R, et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: Causes and consequences. Am J Kidney Dis. 43 (2004), 685–689.
2. Saxena, AK, Panhotra, BR, Sundaram, DS, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control. 31 (2003), 26–33.
3. Gallego, E, López, A, Pérez, J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 104 (2006), c1–c6.
4. Saxena, AK, Panhotra, BR, The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract. 13 (2004), 129–135.
5. Petrosillo, N, Gilli, P, Serraino, D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 37 (2001), 1004–1010.
6. Alfurayh, O, Sabeel, A, Al Ahdal, MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 20 (2000), 103–106.
7. Alavian, SM, Bagheri-Lankarani, K, Mahdavi-Mazdeh, M, Nourozi, S, Hepatitis B and C in dialysis units in Iran: Changing the epidemiology. Hemodial Int. 12 (2008), 378–382.
8. Nemati, E, Taheri, S, Einollahi, B, Sir, D, Hepatitis C among hemodialysis patients: Impact of strict adherence to universal precautions. Hepatitis Monthly. 7 (2007), 245–246.
9. Fabrizi, F, Lunghi, G, Poordad, FF, Martin, P, Novel perspectives on hepatitis B vaccine in dialysis population. Int J Artif Organs. 25 (2002), 174–181.
10. Sali, S, HBV vaccination in chronic renal failure patients. Hepatitis Monthly. 6 (2006), 25–29.
11. Miller, ER, Alter, MJ, Tokars, JI, Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 33 (1999), 356–360.
12. Casciato, DA, McAdam, LP, Kopple, JD, et al. Immunologic abnormalities in hemodialysis patients: Improvement after pyridoxine therapy. Nephron. 38 (1984), 9–16.
13. Kurz, P, Köhler, H, Meuer, S, et al. Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect. Kidney Int. 29 (1986), 1209–1214.
14. Vanholder, R, Van Loo, A, Dhondt, AM, et al. Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant. 11 (1996), 593–598.
15. DaRoza, G, Loewen, A, Djurdjev, O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am J Kidney Dis. 42 (2003), 1184–1192.
16. Rangel, MC, Coronado, VG, Euler, GL, Strikas, RA, Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Vaccine recommendations for patients on chronic dialysis. Semin Dial. 13 (2000), 101–107.
17. Fabrizi, F, Martin, P, Hepatitis B vaccine and dialysis: Current issues. Int J Artif Organs. 24 (2001), 683–694.
18. Fabrizi, F, Dixit, V, Magnini, M, et al. Meta-analysis: Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 24 (2006), 497–506.
19. Fabrizi, F, Andrulli, S, Bacchini, G, et al. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 12 (1997), 1204–1211.
20. Miquilena-Colina, ME, Lozano-Rodrfguez, T, García-Pozo, L, et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine. 27 (2009), 5654–5660.
21. Fabrizi, F, Ganeshan, SV, Dixit, V, Martin, P, Meta-analysis: The adjuvant role of granulocyte macrophagecolony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther. 24 (2006), 789–796.
22. Fabrizi, F, Dixit, V, Martin, P, Meta-analysis: The adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in endstage renal disease. Aliment Pharmacol Ther. 23 (2006), 1559–1566.
23. Krastev, Z, Jelev, D, Antonov, K, et al. Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients—a pilot study. Hepatogastroenterology. 46 (1999), 3184–3188.
24. Sali, S, Alavian, SM, Hajarizadeh, B, Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology (Carlton). 13 (2008), 376–379.
25. Argani, H, Akhtarishojaie, E, Levamizole enhances immune responsiveness to intra-dermal and intramuscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines., 4, 2006, 3.
26. Kayatas, M, Levamisole treatment enhances protective antibody re sponse to hepatitis B vaccination in hemodialysis patients. Artif Organs. 26 (2002), 492–496.
27. Deniz Ayli, M, Ensari, C, Ayli, M, et al. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron. 84 (2000), 291–292.
28. Borenstein, M, et al. Introduction to Meta-Analysis, 2009, John Wiley & Sons, Hoboken, NJ.
29. Begg, CB, Mazumdar, M, Operating characteristics of a rank correlation test for publication bias. Biometrics. 50 (1994), 1088–1101.
30. Egger, M, Davey Smith, G, Schneider, M, Minder, C, Bias in meta-analysis detected by a simple, graphical test. BMJ. 315 (1997), 629–634.
31. Demirci, F, Bayraktaroğlu, Z, Karaoğlan, M, et al. Immunomodulatory effects of HBsAg vaccine and levamisole in chronic hepatitis B and hepatitis B carrier children. Turk J Gastroenterol. 16 (2005), 188–193.
32. Luo, XL, Wang, Y, Tian, GS, et al. Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation [in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 18 (2004), 284–286.
33. Kimball, ES, Experimental modulation of IL-1 production and cell surface molecule expression by levamisole. Ann N Y Acad Sci. 685 (1993), 259–268.
34. Holcombe, RF, Li, A, Stewart, RM, Levamisole and interleukin-2 for advanced malignancy. Biotherapy. 11 (1998), 255–258.
35. Szeto, C, Gillespie, KM, Mathieson, PW, Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology. 100 (2000), 217–224.
36. Staib, L, Link, KH, Beger, HG, Members of the Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT). Toxicity and effects of adjuvant therapy in colon cancer: Results of the German prospective, controlled randomized multicenter trial FOGT-1. J Gastrointest Surg. 5 (2001), 275–281.
37. Holcombe, RF, Milovanovic, T, Stewart, RM, Brodhag, TM, Investigating the role of immunomodulation for colon cancer prevention: Results of an in vivo dose escalation trial of levamisole with immunologic endpoints. Cancer Detect Prev. 25 (2001), 183–191.
38. Johnkoski, JA, Peterson, SM, Doerr, RJ, Cohen, SA, Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines. Cancer Immunol Immunother. 43 (1996), 299–306.
39. Katoch, K, Immunotherapy of leprosy. Indian J Lepr. 68 (1996), 349–361.
40. Printzis, S, Raptopoulou-Gigi, M, Orphanou-Koumerkeridou, H, et al. Immunotherapy in chronic brucellosis. Effect of levamisole and interferon; mechanisms of action and clinical value. Immunopharmacol Immunotoxicol. 16 (1994), 679–693.
41. Fattovich, G, Giustina, G, Brollo, L, et al. Therapy for chronic hepatitis B with lymphoblastoid interferonalpha and levamisole. Hepatology. 16 (1992), 1115–1119.
42. Bosch, O, Moraleda, G, Castillo, I, Carreño, V, Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole. J Hepatol. 19 (1993), 437–441.
43. Ruiz-Moreno, M, García, R, Rua, MJ, et al. Levamisole and interferon in children with chronic hepatitis B. Hepatology. 18 (1993), 264–269.
44. Grishchenko, SV, Lavrukhina, LA, Ketiladze, ES, et al. Results of combined therapy using levamisole for patients with influenza complicated by pneumonia [in Russian]. Vopr Virusol. 29 (1984), 175–179.
45. Janik, J, Kopp, WC, Smith, JW II, et al. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol. 11 (1993), 125–135.
46. Molife, R, Hancock, BW, Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol. 44 (2002), 81–102.
47. Kavanagh, D, Hill, AD, Djikstra, B, et al. Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surgeon. 3 (2005), 245–256.
48. De Brabander, M, Vandebroek, J, Wassenaar, H, et al. Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. Anticancer Res. 15 (1995), 2271–2277.
49. Aksoy, H, Baltaci, S, Türkölmez, K, et al. Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma. Int Urol Nephrol. 33 (2001), 457–459.
50. Link, KH, Kornmann, M, Staib, L, et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: Results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg. 242 (2005), 178–187.
51. Holcombe, RF, McLaren, CE, Milovanovic, T, Immunomodulation with low dose levamisole in patients with colonic polyps. Cancer Detect Prev. 30 (2006), 94–98.
52. Rizzetto, M, Therapy for chronic hepatitis, B, Present status. Minerva Gastroenterol Dietol. 46 (2000), 1–6.
53. Schippinger, W, Jagoditsch, M, Sorré, C, et al., Austrian Breast and Colorectal Cancer Study Group. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer. 92 (2005), 1655–1662.
54. Moher, D, Pham, B, Jones, A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 352 (1998), 609–613.
55. Khan, KS, Daya, S, Jadad, A, The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 156 (1996), 661–666.
56. Ramezani, A, Eslamifar, A, Banifazl, M, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract. 63 (2009), 394–397.
57. Tsouchnikas, I, Dounousi, E, Xanthopoulou, K, et al. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol. 68 (2007), 228–234.